Insider activity at Cogent Biosciences, Inc. has been all selling for a year now: about $383.9 million from six sellers, and zero buyers with their own money.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Zooming out by quarter: Last full quarter: net selling by insiders. Insiders bought in 2 of the last 7 full quarters. 323 investment managers listed COGT in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Morris Arlene | Director | Sell | 3,161 | $37.54 | $119K | SEC |
| Aug 31, 2026 | Morris Arlene | Director | Sell | 42,349 | $37.09 | $1.6M | SEC |
| Mar 31, 2026 | Fairmount Funds Management LLC | Director | Sell | 7,000,000 | $34.66 | $242.6M | SEC |
| Jan 22, 2026 | Fairmount Funds Management LLC | Director | Sell | 3,500,000 | $36.40 | $127.4M | SEC |
| Dec 30, 2025 | Kearns Evan | Executive Officer | Sell | 65,000 | $38.70 | $2.5M | SEC |
| Dec 30, 2025 | Green John L. | CFO | Sell | 77,000 | $38.68 | $3.0M | SEC |
| Dec 30, 2025 | Sachs Jessica | Executive Officer | Sell | 82,642 | $38.70 | $3.2M | SEC |
| Dec 30, 2025 | Robinson John Edward | Executive Officer | Sell | 90,000 | $38.74 | $3.5M | SEC |
| Jul 14, 2025 | Fairmount Funds Management LLC | Director | Buy | 2,777,777 | $9.00 | $25.0M | SEC |
| Jan 15, 2025 | Pinnow Cole | Executive Officer | Buy | 43,750 | $7.60 | $332K | SEC |
| Jun 13, 2023 | Fairmount Funds Management LLC | 10% Owner | Buy | 800,000 | $12.00 | $9.6M | SEC |
In the last 12 months Cogent Biosciences, Inc. insiders made open-market purchases worth about $0 and sales worth about $383.9 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in COGT was filed on 2026-08-31.
323 investment managers reported holding COGT in SEC Form 13F filings for Q2 2026.
No congressional trades in COGT were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).